Nano and microtechnologies for ophthalmic administration, an overview

Journal of Drug Delivery Science and Technology

Volumn 23, Issue 2, 2013, Pages 75-102

  Herrero Vanrell, R ^a   Vicario De La Torre, M ^a   Andres Guerrero V ^a   Barbosa Alfaro, D ^a   Molina Martinez I T ^a   Bravo Osuna, I ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Biomaterials; Dendrimers; Intraocular administration; Liposomes; Microemulsions; Microparticles; Nanoparticles; Niosomes; Ophthalmic topical administration; Periocular administration

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CELECOXIB; CHITOSAN; DENDRIMER; DEXAMETHASONE; FLUOROURACIL; GANCICLOVIR; HYALURONIC ACID; LIPID EMULSION; LIPOSOME; NIOSOME; POLYCAPROLACTONE; POLYGLACTIN; POLYLACTIC ACID; SOLID LIPID NANOPARTICLE;

DIABETIC MACULAR EDEMA; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG STERILITY; DRUG TOLERANCE; FREEZE DRYING; HUMAN; LIPID BILAYER; LIPID VESICLE; MICROEMULSION; MICROTECHNOLOGY; NANOFABRICATION; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; RETINA VEIN OCCLUSION; REVIEW; UVEITIS;

EID: 84876531151     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(13)50016-5     Document Type: Review

References (297)

1. Urtti A. - Challenges and obstacles of ocular pharmacokinetics and drug delivery. - Adv. Drug Deliv. Rev., 58 (11), 1131-1135, 2006.
2. Yasukawa T., Ogura Y., Tabata Y., Kimura H., Wiedemann P., Honda Y. - Drug delivery systems for vitreoretinal diseases. -Prog. Retin. Eye Res., 23 (3), 253-281, 2004. (Pubitemid 38737129)
3. Cardillo J.A., Souza-Filho A.A., Oliveira A.G. - Intravitreal bioerudivel sustained-release triamcinolone microspheres system (RETAAC). Preliminary report of its potential usefulnes for the treatment of diabetic macular edema. - Arch. Soc. Esp. Oftalmol., 81 (12), 675-677, 679-681, 2006.
4. Amrite A.C., Edelhauser H.F., Singh S.R., Kompella U.B. - Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. - Mol. Vis., 14, 150-160, 2008. (Pubitemid 351194002)
5. Kothuri M.K., Pinnamaneni S., Das N.G., Das S.K. - Microparticles and nanoparticles in ocular drug delivery - In: Ophthalmic Drug Delivery Systems, M. Dekker, New York, 2003, p. 437-466.
6. Hou D., Xie C., Huang K., Zhu C. - The production and characteristics of solid lipid nanoparticles (SLNs). - Biomaterials., 24 (10), 1781-1785, 2003. (Pubitemid 36184733)
7. Schwarz C., Mehnert W., Lucks J.S., Müller R.H. - Solid lipid nanoparticles (SLN) for controlled drug delivery I. Production, characterization and sterilization. - J. Control. Rel., 30 (1), 83-96, 1994. (Pubitemid 24173181)
8. Bourges J.L. et al. - Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. - Invest. Ophthalmol. Vis. Sci., 44 (8), 3562-3569, 2003.
9. Aukunuru J.V., Ayalasomayajula S.P., Kompella U.B. - Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. - J. Pharm. Pharmacol., 55 (9), 1199-1206, 2003. (Pubitemid 37180005)
10. Bejjani R.A. et al. - Nanoparticles for gene delivery to retinal pigment epithelial cells. - Mol. Vis., 11, 124-132, 2005. (Pubitemid 41358300)
11. Paolicelli P., de la Fuente M., Sanchez A., Seijo B., Alonso M.J. - Chitosan nanoparticles for drug delivery to the eye. - Expert Opin. Drug Deliv., 6 (3), 239-253, 2009.
12. du Toit P.V., Choonara Y.E., Govender T., Carmichale T. - Ocular drug delivery- a look towards nanobioadhesives. - Expert Opin. Drug Deliv., 8 (1), 71-94, 2011.
13. Bangham A.D., Standish M.M., Watkins J.C. - Diffusion of univalent ions across the lamellae of swollen phospholipids. - J. Mol. Biol., 13 (1), 238-252, 1965.
14. Le Bourlais C., Acar L., Zia H., Sado P.A., Needham T., Leverge R. - Ophthalmic drug delivery systems, Recent advances. -Progress in Retinal and Eye Research, 17 (1), 33-58, 1998. (Pubitemid 28040752)
15. Samad A., Sultana Y., Aqil M. - Liposomal drug delivery systems: an update review. - Curr. Drug Deliv., 4 (4), 297-305, 2007. (Pubitemid 47554274)
16. Meisner D., Mezei M. - Liposome ocular delivery systems. - Adv. Drug Del. Rev., 16 (1), 75-93, 1995.
17. Mainardes R.M. et al. - Colloidal carriers for ophthalmic drug delivery. - Curr. Drug Targets, 6 (3), 363-371, 2005. (Pubitemid 40667801)
18. Elorza B., Elorza M.A., Sainz M.C., Chantres J.R. - Comparison of particle size and encapsulation parameters of three liposomal preparations. - J. Microencapsulation, 10 (2), 237-248, 1993. (Pubitemid 23184658)
19. Nii T., Ishii F. - Encapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle method. - Int. J. Pharm., 298 (1), 198-205, 2005. (Pubitemid 40828340)
20. Law S.L., Huang K.J., Chiang C.H. - Acyclovir-containing liposomes for potential ocular delivery: corneal penetration and absorption. - J Control. Rel., 63 (1-2), 135-140, 2000. (Pubitemid 30046949)
21. Simmons S.T., Sherwood M.B., Nichols D.A., Penne R.B., Sery T., Spaeth G.L. - Pharmacokinetics of a 5-fluorouracil liposomal delivery system. - Br. J. Ophthalmol., 72 (9), 688-691, 1988.
22. Moon J.W., Song Y.K., Jee J.P., Kim C.K., Choung H.K., Hwang J.M. - Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits. - Invest. Ophthalmol. Vis. Sci., 47 (9), 3968-3974, 2006.
23. Shakiba S. et al. - Antiviral effect in human cytomegalovirus-infected cells, pharmacokinetics, and intravitreal toxicology in rabbits of acyclovir diphosphate dimyristoylglycerol. - Antimicrob. Agents Chemother., 39 (6), 1383-1385, 1995.
24. Cheng L. et al. - Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug. - Invest. Ophthalmol. Vis. Sci., 40 (7), 1487-1495, 1999. (Pubitemid 29252340)
25. Cheng L. et al. - Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. - Invest. Ophthalmol. Vis. Sci., 41 (6), 1523-1532, 2000. (Pubitemid 30261879)
26. Crooke S.T. - Vitravene, another piece in the mosaic. - Antisense Nucleic Acid Drug Dev., 8 (4), vii-viii, 1998.
27. Hangai M K.Y., Tanihara H, Honda Y. - In vivo gene transfer into the retina mediated by a novel liposome system. - Invest. Ophthalmol. Vis. Sci., 37 (13), 2678-2685, 1996. (Pubitemid 27026552)
28. Bochot A., Couvreur P., Fattal E. - Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. - Prog. Retin. Eye Res., 19 (2), 131-147, 2000.
29. Hashida M., Kawakami M., Yamashita F. - Lipid carrier systems for targeted drug and gene delivery. - Chem. Pharm. Bull., 53 (8), 871-880, 2005. (Pubitemid 41327672)
30. Abul-Hassan K., Walmsley R., Boulton M. - Optimization of nonviral gene transfer to human primary retinal pigment epithelial cells. - Curr. Eye Res., 20 (5), 361-366, 2000. (Pubitemid 30614572)
31. Naik R., Mukhopadhyay A., Ganguli M. - Gene delivery to the retina: focus on non-viral approaches. - Drug Discov. Today, 14 (5-6), 306-315, 2009.
32. Vandamme T.F. - Microemulsions as ocular drug delivery systems: recent developments and future challenges. - Prog. Retin. Eye Res., 21 (1), 15-34, 2002. (Pubitemid 34242705)
33. Sahoo S., Dilnawaz F., Krishnakumar S. - Nanotechnology in ocular drug delivery. - Drug Discov. Today, 13 (3-4), 144-151, 2008.
34. Patravale V.B., Date, A.A., Kulkarni R.M. - Nanosuspensions: a promising drug delivery strategy. - J. Pharm. Pharmacol., 56 (7), 827-840, 2004. (Pubitemid 38885975)
35. Kahlweit M., Strey R., Busse G. - Microemulsions: a qualitative thermodynamic approach. - J. Phys. Chem., 94 (10), 3881-3894, 1990.
36. Kahlweit M., Strey R., Busse G. - Weakly to strongly structured mixtures. - Phys. Rev., E 47, 4197-4209, 1993.
37. Lawrence M.J., Rees G.D. - Microemulslon-based media as novel drug delivery systems. - Adv. Drug Del. Rev., 45 (1), 89-121, 2000.
38. Abdelbary G., El-Gendy N. - Niosome-encapsulated gentamicin for ophthalmic controlled delivery. - AAPS PharmSciTech., 9 (3), 740-747, 2008.
39. Abdelkader H., Ismail S., Kamal A., Alany R.G. - Design and evaluation of controlled-release niosomes and discomes for naltrexone hydrochloride ocular delivery. - J. Pharm. Sci., 100 (5), 1833-1846, 2011.
40. Aggarwal D., Garg A., Kaur I.P. - Development of a topical niosomal preparation of acetazolamide: preparation and evaluation. - J. Pharm. Pharmacol., 56 (12), 1509-1517, 2004. (Pubitemid 39601991)
41. Aggarwal D., Kaur I.P. - Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. - Int. J. Pharm., 290 (1-2), 155-159, 2005. (Pubitemid 40139055)
42. Abdelkader H., Wu Z., Al-Kassas R., Alany R.G. - Niosomes and discomes for ocular delivery of naltrexone hydrochloride: Morphological, Theological, spreading properties and photoprotective effects. - Int. J. Pharm., 433 (1-2), 142-148, 2012.
43. Aulenta F., Hayes W., Rannard S. - Dendrimers: a new class of nanoscopic containers and delivery device. - Eur. Pol. J., 39, 1741-1771, 2003.
44. Gillies E.R., Frechet J.M. - Dendrimers and dendritic polymers In drug delivery. - Drug Discov. Today, 10 (1), 35-43, 2005. (Pubitemid 40164817)
45. Gupta U., Agashw H.B., Asthana A., Jain N.K. - A review on in vitro-in vivo Investigations on dendrimers: the novel nanoscopic drug carrier. - Nanomedicine, 2, 66-73, 2006. (Pubitemid 43956608)
46. Svenson S. - Dendrimers as versatile platform in drug delivery applications. - Eur. J. Pharm. Biopharm., 71 (3), 445-462, 2009.
47. Boas U., Heegaard P.M. - Dendrimers in drug research. - Chem. Soc. Rev., 33 (1), 43-63, 2004.
48. Svenson S., Tomalia D.A. - Dendrimers in biomedical applications, Reflections on the field. - Adv. Drug Deliv. Rev., 57 (15), 2106-2129, 2005. (Pubitemid 41759389)
49. Esfand R., Tomalia D.A. - Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. - Drug Discov. Today, 6 (8), 427-436, 2001. (Pubitemid 32328297)
50. Kukowska-Latallo J.F. et al. - Nanoparticle targeting of anticancer drug Improves therapeutic response in animal model of human epithelial cancer. - Cancer Res., 65 (12), 5317-5324, 2005. (Pubitemid 40827344)
51. Thomas T.P. et al. - Targeting and inhibition of cell growth by an engineered dendritic nanodevice. - J. Med. Chem., 48 (11), 3729-3735, 2005. (Pubitemid 40776848)
52. Patri A.K., Majoras I.J., Baker J.R. - Dendritic polymer macromolecular carriers for drug delivery. - Curr. Opin. Chem. Biol., 6 (4), 466-471, 2002. (Pubitemid 34804769)
53. Khandare J., Calderon M., Dagia N.M., Haag R. - Multifunctional dendritic polymers in nanomedicine: opportunities and challenges. - Chem. Soc. Rev., 2011.
54. Herrero-Vanrell R., Refojo M.F. - Biodegradable microspheres for vitreoretinal drug delivery. - Adv. Drug Deliv. Rev., 52 (1), 5-16, 2001. (Pubitemid 32973634)
55. D'Mello S.R., Das S.K., Das N.G. - Polymeric nanoparticles for small-molecule. - In: Drug Delivery Nanoparticles, Formulation and Characterization, Thassu Y. Ed., Informa Healthcare USA, Inc., New York, 2009, p. 16-34.
56. Li V.H., Wood R.W., Kreuter J., Harmia T., Robinson J.R. -Ocular drug delivery of progesterone using nanoparticles. - J. Microencapsul., 3 (3), 213-218, 1986. (Pubitemid 17195137)
57. Vauthier C., Dubernet C., Fattal E., Pinto-Alphandary H., Couvreur P. - Poly(alkylcyanoacrylates) as biodegradable materials for biomedical applications. - Adv. Drug Deliv. Rev., 55 (4), 519-548, 2003. (Pubitemid 36423302)
58. Wang J.J. et al. - Recent advances of chitosan nanoparticles as drug carriers. - Int. J. Nanomedicine, 6, 765-774, 2011.
59. Nagpal K., Singh S.K., Mishra D.N. - Chitosan nanoparticles: a promising system in novel drug delivery. - Chem. Pharm. Bull. (Tokyo)., 58 (11), 1423-1430, 2010.
60. Mao H.Q. et al. - Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. - J. Control. Rel., 70 (3), 399-421, 2001.
61. Bravo-Osuna I. et al. - Interfacial interaction between transmembrane ocular mucins and adhesive polymers and dendrimers analyzed by surface plasmon resonance. - Pharm. Res., 29 (8), 2329-2340, 2012.
62. De Campos A.M., Sanchez A., Gref R., Calvo P., Alonso M.J. - The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. - Eur. J. Pharm. Sci., 20 (1), 73-81, 2003. (Pubitemid 37103234)
63. Mahmoud A.A., El-Feky G.S., Kamel R., Awad G.E. - Chitosan/ sulfobutylether-beta-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. - Int. J. Pharm., 413 (1-2), 229-236, 2011.
64. Nagarwal R.C., Singh P.N., Kant S., Maiti P., Pandit J.K. - Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in vitro and in vivo study. - Chem. Pharm. Bull. (Tokyo), 59 (2), 272-278, 2011.
65. Badawi A.A., El-Laithy H.M.,El Qidra R.K.,El Mofty H.,El dally M. - Chitosan based nanocarriers for indomethacin ocular delivery. - Arch. Pharm. Res., 31 (8), 1040-1049, 2008.
66. de Campos A.M., Diebold Y., Carvalho E.L., Sanchez A., Alonso M.J. - Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity. - Pharm. Res., 21 (5), 803-810, 2004.
67. Motwani S.K., Chopra S., Talegaonkar S., Kohli K., Ahmad F.J., Khar R.K. - Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. - Eur. J. Pharm. Biopharm., 68 (3), 513-525, 2008. (Pubitemid 351318222)
68. Bhatta R.S., et al. - Mucoadhesive nanoparticles for prolonged ocular delivery of natamycin: in vitro and pharmacokinetics studies. - Int. J. Pharm., 432 (1-2), 105-112, 2012.
69. de la Fuente M., Seijo B., Alonso M.J. - Novel hyaluronic acid-chitosan nanoparticles for ocular gene therapy. - Invest. Ophthalmol. Vis. Sci., 49 (5), 2016-2024, 2008.
70. Contreras-Ruiz L. et al. - Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells. - Mol. Vis., 17, 279-290, 2011.
71. Diebold Y. et al. - Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). - Biomaterials, 28 (8), 1553-1564, 2007. (Pubitemid 46027250)
72. London N.J.,Chiang A., Haller J.A. - The dexamethasone drug delivery system: indications and evidence. - Adv. Ther., 28 (5), 351-366, 2011.
73. Colthrust M.J., Williams R.L., Hiscott P.S., Grierson I. - Biomaterials used in the posterior segment of the eye. - Biomaterials., 21, 649-665, 2000. (Pubitemid 30109156)
74. Hurrell S., Cameron R.E. - The effect of initial polymer morphology on the degradation and drug release from polyglycolide. - Biomaterials, 23 (11), 2401-2409, 2002. (Pubitemid 34234842)
75. Panyam J. et al. - Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. - J. Control. Rel., 92 (1-2), 173-187, 2003.
76. Veya E. et al. - Degradation mechanism of poly(lactic-co-glycolic) acid block copolymer cast films in phosphate buffer solution. -Polym. Degrad. Stab., 93 (10), 1869-1876, 2008.
77. Williams H.E. et al. - The effect of gamma-irradiation and polymer composition on the stability of PLG polymer and microspheres. - Polym. Degrad. Stab., 91, 2171-2181, 2006. (Pubitemid 43817140)
78. Ramchandania M., Pankaskieb M., Robinson D. - The influence of manufacturing procedure on the degradation of poly(lactide-co-glycolide) 85:15 and 50:50 implants. - J. Control. Rel., 43, 161-173, 1997. (Pubitemid 26390965)
79. Delgado A., Llabrés M. - Degradation of DL-PL-methadone for Intravitreal administration. - J. Control. Rel., 99, 41-52, 1996.
80. Hung-Hong L., Shiu-Man K., Li-Ren H., Yi-Hug T. - The preparation of norfloxacin-loaded liposomes and their in vitro evaluation in pig's eye. - J. Pharm. Pharmacol., 48 (8), 801-805, 1996.
81. Maruyama K., Yuda T., Okamoto A., Kojima S., Suginaka A., Iwatsuru M. - Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). - Biochim. Biophys. Acta, 1128 (1), 44-49, 1992.
82. Gabizon A., Horowitz A.T., Goren D., Tzemach D., Shmeeda H., Zalipsky S. - In vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing mice. - Clin. Cancer Res., 9 (17), 6551-6559, 2003. (Pubitemid 38031844)
83. Liebler D.C., Kling D., Reed D.J. - Antioxidant protection of phospholipid bilayers by alpha-tocopherol. Control of alpha-tocopherol status and lipid peroxidation by ascorbic acid and glutathione. - J. Biol. Chem., 261 (26), 12114-12119, 1986. (Pubitemid 17202771)
84. Niki E., Noguchi N., Tsuchihashi H., Gotoh N. - Interaction among vitamin C, vitamin E, and beta-carotene. - Am. J. Clin. Nutr., 62 (6 Suppl), 1322S-1326S, 1995.
85. Vemuri S., Rhodes C.T. - Preparation and characterization of liposomes as therapeutic delivery systems: a review. - Pharm. Acta Helv., 70 (2), 95-111, 1995.
86. Sharma A., Sharma U.S. - Liposomes in drug delivery: Progress and limitations. - Int. J. Pharm., 154 (2), 123-140, 1997. (Pubitemid 27351317)
87. Feng-Feng L.V., Zheng L.Q., Tung C.H. - Phase behavior of the microemulsions and the stability of the chloramphenicol in the microemulsion-based ocular drug delivery system. - Int. J. Pharm., 301 (1-2), 237-246, 2005.
88. López-Quintela M.A.,Tojo, C., Blanco, M.C., García Rio, L., Leis J. R. - Microemulsion dynamics and reactions in microemulsions. - Curr. Opin. Colloid Interface Sci., 9 (3-4), 264-278, 2004.
89. Haße A., Keipert, S. - Development and characterization of microemulsions for ocular application. - Eur. J. Pharm. Biopharm., 43 (2), 179-183, 1997. (Pubitemid 28298799)
90. Tamilvanan S. - Oil-in-water lipid emulsions: implications for parenteral and ocular delivering systems. - Prog. Lipid Res., 43 (6), 489-533, 2004. (Pubitemid 39441344)
91. Tomalia D.A., Baker H., Dewald J.M., Hall M., Martin S., Roeck J., Ryder J., Smith P. - A new class of polymers: Starburst-dendritic macromolecules. - Polym J., 17, 117-132, 1985.
92. Hawker C.J., Frechet J.M.J. - Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. - J. Am. Chem. Soc., 112, 7638-7647, 1990.
93. Arnáiz E.D., García-Gallego S., Urbiola K., Gómez R., Tros de llarduya C., de la Mata F.J. - Synthesis of cationic carbosilane dendrimers via click chemistry and their use as effective carriers for DNA transfection into cancerous cells. - Mol. Pharm., 9 (3), 433-437, 2012.
94. Al-Jamal K.T., Ramaswamy C., Florence A.T. - Supramolecular structures from dendrons and dendrimers. - Adv. Drug Deliv. Rev., 57 (15), 2238-2270, 2005.
95. Qiu L.Y., Bae Y.H. - Polymer architecture and drug delivery. -Pharm Res., 23 (1), 1-30, 2006.
96. Biricova V., Laznickova A. - Dendrimers: analytical characterization and applications. - Bioorg. Chem., 37 (6), 185-192, 2009.
97. Duncan R., Izzo L. - Dendrimer biocompatibility and toxicity. -Adv. Drug Deliv. Rev., 57 (15), 2215-2237, 2005.
98. Beg S., Samad A., Alam M.I., Nazish I. - Dendrimers as novel systems for delivery of neuropharmaceuticals to the brain. - CNS Neural. Disord. Drug Targets, 10 (5), 576-588, 2011.
99. Xu Q., Wang C.H., Pack D.W. - Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. - Curr Pharm Des., 16 (21), 2350-2368, 2010.
100. Freitas S., Merkle H.P., Gander B. - Microencapsulation by solvent extraction/evaporation: reviewing the state of the art of microsphere preparation process technology. - J. Control. Rel., 102 (2), 313-332, 2005. (Pubitemid 40093756)
101. Paganelli F. et al. - A single intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery. - Invest. Ophthalmol. Vis. Sci., 50 (7), 3041-3047, 2009.
102. Andrieu-Soler C. et al. - Intravitreous injection of PLGA microspheres encapsulating GDNF promotes the survival of photoreceptors in the rd1/rd1 mouse. - Mol. Vis., 11, 1002-1011, 2005. (Pubitemid 41715739)
103. van de Weert M., Hennink W.E., Jiskoot W. - Protein instability in poly(lactic-co-glycolic acid) microparticles. - Pharm. Res., 17, 1159-1167, 2000.
104. Blanco D., Alonso M.J. - Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants. - Eur. J. Pharm. Biopharm., 45 (3), 285-294, 1998. (Pubitemid 28270817)
105. Garbayo E., Ansorena E., Lanciego J.L., Aymerich M.S., Blanco-Prieto M.J. - Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. - Eur. J. Pharm. Biopharm., 69 (3), 844-851, 2008.
106. Checa-Casalengua P. et al. - Retinal ganglion cells survival in a glaucoma model by GDNFA/it E PLGA microspheres prepared according to a novel microencapsulation procedure. - J. Control. Rel., 156 (1), 92-100, 2011.
107. Yuan W.R.T., Wu F., Zhao H., Jin T - A novel preparation method for microspheres by glycerol modified slid-in-oil-in-water multiemulsion. - Polym. Adv. Technol., 21, 371-376, 2010.
108. Patil G. - Biopolymer albumin for diagnosis and in drug delivery. - Drug Dev Res., 58, 219-247, 2003. (Pubitemid 36555058)
109. Coester C.J., Langer K., van Briesen H., Kreuter J. - Gelatin nanoparticles by two step desolvation, A new preparation method, surface modifications and cell uptake. - J. Microencapsul., 17 (2), 187-193, 2000. (Pubitemid 30135796)
110. Csaba N., Köping-Höggard M., Alonso M.J. - Ionically crosslinked chitosan/tripolyphosphate nanoparticles for oligonucleotide and Plasmid DNA delivery. - Int. J. Pharm., 382 (1-2), 205-214, 2009.
111. Calvo P., Vila-Jato J.L., Alonso M.J. - Evaluation of cationic polymer-coated nanocapsules as ocular drug carriers. - Int. J. Pharm., 153, 41-50, 1997. (Pubitemid 27283332)
112. Boonsongrit Y., Mitrevej A., Mueller B.W. - Chitosan drug binding by ionic interaction. - Eur. J. Pharm. Biopharm., 62 (3), 267-274, 2006. (Pubitemid 43356575)
113. Ueda M., Kreuter J. - Optimization of the preparation of loperamide-loaded poly (L-lactide) nanoparticles by high pressure emulslfication-solvent evaporation. - J. Microencapsul., 14 (5), 593-605, 1997. (Pubitemid 27380191)
114. Xiong S., Zhao X., Heng B.C., Ng K.W., Loo J.S. - Cellular uptake of poly-(D,L-lactide-co-glycolide) (PLGA) nanoparticles synthesized through solvent emulsion evaporation and nanoprecipitation method. - Biotechnol. J., 6 (5), 501-508, 2011.
115. Ravi Kumar M.N. - Nano and microparticles as controlled drug delivery devices. - J. Pharm. Pharm. Sci., 3 (2), 234-258, 2000.
116. Li X., Anton N., Arpagaus C., Belleteix F., Vandamme T.F. - Nanoparticles by spray drying using Innovative new technology: the Büchi nano spray dryer B-90. - J. Control. Rel., 147 (2), 304-310, 2010.
117. Barichello J.M., Morishita M., Takayama K., Nagai T. - Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. - Drug Dev. Ind. Pharm., 25 (4), 471-476, 1999. (Pubitemid 29159426)
118. Szoka F., Papahadjopoulos D. - Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. - Proc. Natl. Acad. Sci. USA, 75 (9), 4194-4198, 1978. (Pubitemid 9025976)
119. Ebrahim S., Peyman G.A., Lee P.J. - Applications of liposomes in ophthalmology. - Surv. Ophthalmol., 50 (2), 167-182, 2005.
120. Szoka F., Papahadjopoulos D. - Comparative properties and methods of preparation of lipid vesicles (liposomes). - Annu. Rev. Biophys. Bioeng., 9 (1), 467-508, 1980.
121. Hope M.J., Bally M.B., Webb G. - Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. - Biochim. Biophys. Acta, 812 (1), 55-65, 1985. (Pubitemid 15159822)
122. Mayer L.D., Hope M.J., Cullis P.R., Janoff A.S. - Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles. - Biochim. Biophys. Acta, 817 (1), 193-196, 1985.
123. Mozafari M.R. - Liposomes: an overview of manufacturing techniques. - Cell Mol. Biol. Lett., 10 (4), 711-719, 2005.
124. D'Emanuele A., Attwood D. - Dendrimer-drug interactions. - Adv. Drug Deliv. Rev., 57 (15), 2147-2162, 2005.
125. Yang H., Kao W.J. - Dendrimers for pharmaceutical and biomedical applications. - J. Biomater. Sci. Polym. Ed., 17 (1-2), 3-19, 2006.
126. Yiyun C., Tongwen X. - Dendrimers as potential drug carriers. Part I. Solubilization of non-steroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. - Eur. J. Med. Chem., 40 (11), 1188-1192, 2005. (Pubitemid 41446292)
127. Namazi H., Adeli M. - Dendrimers of citric acid and poly (ethylene glycol) as the new drug-delivery agents. - Biomaterials, 26 (10), 1175-1183, 2005. (Pubitemid 39286827)
128. Na M. et al. - Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by In vitro and in vivo studies. - Eur. J. Med. Chem., 41 (5), 670-674, 2006. (Pubitemid 43766801)
129. Asthana A., Chauhan A.S., Diwan P.V., Jain N.K. -Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled site-specific delivery of acidic anti-inflammatory active ingredient. - AAPS PharmSciTech., 6 (3), E536-542, 2005.
130. Bhadra D., Yadav A.K., Bhadra S., Jain N.K. - Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. - Int. J. Pharm., 295 (1-2), 221-233, 2005. (Pubitemid 40558805)
131. Padilla De Jesus O.L., Ihre H.R., Gagne L., Frechet J. M., Szoka F.C, Jr. - Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. - Bioconjug. Chem., 13 (3), 453-461, 2002. (Pubitemid 34535938)
132. D'Emanuele A., Jevprasesphant R., Penny J., Attwood D. -The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. - J. Control. Rel., 95 (3), 447-453, 2004. (Pubitemid 38340495)
133. Kolhe P., Khandare J., Pillai O., Kannan S., Lieh-Lai M., Kannan R.M. - Preparation, cellular transport, and activity of polyamidoamine-based dendritic nanodevices with a high drug payload. - Biomaterials, 27 (4), 660-669, 2006. (Pubitemid 41464262)
134. Gurdag S., Khandare J., Stapels S., Matherly L.H., Kannan R.M. - Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. - Bioconjug. Chem., 17 (2), 275-283, 2006.
135. Mishra M.K. et al. - PAMAM dendrimer-azithromycin conjugate nanodevices for the treatment of Chlamydia trachomatis infections. - Nanomedicine, 7 (6), 935-944, 2011.
136. Dufes C., Uchegbu I.F., Schatzlein A.G. - Dendrimers in gene delivery. - Adv. Drug Deliv. Rev., 57 (15), 2177-2202, 2005.
137. Tiera M.J., Shi Q., Winnik F.M., Fernandes J.C. - Polycation-based gene therapy: current knowledge and new perspectives. - Curr Gene Then, 11 (4), 288-306, 2011.
138. Manunta M., Tan PH., Sagoo P., Kashefi K., George A.J. - Gene delivery by dendrimers operates via a cholesterol dependent pathway. - Nucleic Acids Res., 32 (9), 2730-2739, 2004. (Pubitemid 38885944)
139. Cai X., Nash Z., Conley S.M., Fliesler S.J., Cooper M.J., Naash M.I. - A partial structural and functional rescue of a retinitis pigmentosa model with compacted DNA nanoparticles. - PLoS One, 4 (4), e5290, 2009.
140. Diebold Y., Calonge M. - Applications of nanoparticles in ophthalmology. - Prog. Retin. Eye Res., 29 (6), 596-609, 2010.
141. Geroski D.H., Edelhauser H.F. - Drug delivery for posterior segment eye disease. - Invest. Ophthalmol. Vis. Sci., 41 (5), 961-964, 2000. (Pubitemid 30187528)
142. Geroski D.H., Edelhauser H.F. - Transscleral drug delivery for posterior segment disease. - Adv. Drug Deliv. Rev., 52 (1), 37-48, 2001. (Pubitemid 32973637)
143. Ambati J., Adamis A.P. - Transscleral drug delivery to the retina and choroid. - Prog. Retin. Eye Res., 21 (2), 145-151, 2002. (Pubitemid 34607434)
144. Conley S.M., Naash M.I. - Nanoparticles for retinal gene therapy. - Prog. Retin. Eye Res., 29 (5), 376-397, 2010.
145. Herrero-Vanrell R., Ramirez L., Fernandez-Carballido A., Refojo M.F. - Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process. - Pharm Res., 17 (10), 1323-1328, 2000.
146. Nijsen J.R et al. - Influence of neutron irradiation on holmium acetylacetonate loaded poly(L-lactic acid) microspheres. - Biomaterials, 23 (8), 1831-1839, 2002.
147. Sintzel M.B., Schwach-Abdellaoui K., Mäder K., Stösser R., Heller J., Tabatabay C., Gurny R. - Influence of irradiation sterilization on a semi-solid poly(ortho ester). - Int. J. Pharm., 175, 165-176, 1998. (Pubitemid 28517972)
148. Martinez-Sancho C., Herrero-Vanrell R., Negro S. - Optimisation of aciclovir poly(D,L-lactide-co-glycolide) microspheres for intravitreal administration using a factorial design study. - Int. J. Pharm., 273 (1-2), 45-56, 2004. (Pubitemid 38317039)
149. Amrite A.C., Ayalasomayajula S.P., Cheruvu N.P., Kompella U.B. - Single periocular injection of celecoxib-PLGA microparticles inhibits diabetes-induced elevations in retinal PGE2, VEGF, and vascular leakage. - Invest. Ophthalmol. Vis. Sci., 47 (3), 1149-1160, 2006. (Pubitemid 46768351)
150. Shulkin P.M., Davisab M.A., Adams D.F.-Lyophilized liposomes: a new method for long-term vesicular storage. - J. Microencapsul., 1, 73-80., 1984.
151. van Winden E.C.A., Zhang W., Crommelin D.J.A. - Effect of freezing rate on the stability of liposomes during freeze-drying and rehydration. - Pharm. Res., 14 (9), 1151-1160, 1997. (Pubitemid 27432536)
152. Chen C., Han D., Cai C., Tang X. - An overview of liposome lyophilization and its future potential. - J. Control. Rel., 142 (3), 299-311, 2010.
153. Mohammed A.R.B.V., Coombes A.C., Perrie Y. - Lyophilisation and sterilisation of liposomal vaccines to produce stable and sterile products. - Methods Rind. Exp. Clin. Pharmacol., 40, 30-38), 2006.
154. Ohtake S., Schebor C., de Pablo J.J. - Effects of trehalose on the phase behavior of DPPC-cholesterol unilamellar vesicles. -Biochim. Biophys. Acta (BBA), Biomembranes, 1758 (1), 65-73, 2006.
155. Peer D., Florentin A., Margalit R. - Hyaluronan is a key component in cryoprotection and formulation of targeted unilamellar liposomes. - Biochim. Biophys. Acta (BBA), Biomembranes, 1612 (1), 76-82, 2003. (Pubitemid 36555689)
156. Ugwu S., Parmar M., Miller B., Sardone T., Peikov V., Ahmad I. - Preparation, characterization, and stability of liposome-based formulations of mitoxantrone. - Drug Dev. Ind. Pharm., 31 (2), 223-229, 2005. (Pubitemid 40315717)
157. Tardi C., Drechsler M., Bauer K.H., Brandi M. - Steam sterilisation of vesicular phospholipid gels. - Int. J. Pharm., 217 (1-2), 161-172, 2001. (Pubitemid 32268643)
158. Mohammed A.R.B.V., Kirby D.J., McNeil S.E., Perrie Y. - Increased potential of a cationic liposome-based delivery system: enhancing stability and sustained immunological activity in pre-clinical development. - Eur. J. Pharm. Biopharm., 76 (3), 404-412, 2010.
159. El Maghraby G.M., Bosela A.A. - Investigation of self-microemulsifying and microemulsion systems for protection of prednisolone from gamma radiation. - Pharm. Dev. Technol., 16 (3), 237-242, 2011.
160. Andrés-Guerrero V., Vicario-de-la-Torre M., Molina-Martinez I.T., Benítez-del-Castillo J.M., García-Feijoo J., Herrero-Vanrell R. - Comparison of the in vitro tolerance and in vivo efficacy of traditional timolol maleate eye drops versus new formulations with bioadhesive polymers. - Invest. Ophthalmol. Vis. Sci., 52 (6), 3548-3556, 2011.
161. Andres-Guerrero V., Alarma-Estrany P., Molina-Martinez I.T., Peral A., Herrero-Vanrell R., Pintor J. - Ophthalmic formulations of the intraocular hypotensive melatonin agent 5-MCA-NAT -Exp. Eye Res., 88 (3), 504-511, 2009.
162. Andrés-Guerrero V., Molina-Martínez I.T., Peral A., de las Heras B., Pintor J., Herrero-Vanrell R. - The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes. - Invest. Ophthalmol. Vis. Sci., 52 (3), 1507-1515, 2011.
163. Brasnu E., Brignole-Baudouin F., Riancho L., Guenoun J.M., Warnet J.M., Baudouin C. - In vitro effects of preservative-free tafluprost and preserved
164. Ayaki M., Iwasawa A., Yaguchi S., Koide R. - Preserved and unpreserved 12 anti-allergic ophthalmic solutions and ocular surface toxicity: in vitro assessment in four cultured corneal and conjunctival epithelial cell lines. - Biocontrol. Sci., 15 (4), 143-148, 2010.
165. Ayaki M., Iwasawa A., Yaguchi S., Koide R. - In vitro assessment of the cytotoxicity of anti-allergic eye drops using 5 cultured corneal and conjunctival cell lines. - J. Oleo Sci., 60 (3), 139-144, 2011.
166. Kaczmarek R., Szurman P., Misiuk-Hojto M., Grzybowski A. - Antiproliferative effects of preservative-free triamcinolone acetonide on cultured human retinal pigment epithelial cells. -Med. Sci. Monit., 15 (8), 227-231, 2009.
167. Sunshine J.C., Sunshine S.B., Bhutto I., Handa J.T., Green J.J. - Poly(β-amino ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo. - PLoS One, 7 (5), e37543, 2012.
168. Wang C.H., Hwang Y.S., Chiang P.R., Shen C.R., Hong W.H., Hsiue G.H. - Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel. - Biomacromolecules, 13 (1), 40-48, 2012.
169. Yamagishi R., Aihara M., Araie M. - Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. - Exp. Eye Res., 93 (3), 265-270, 2011.
170. Contreras-Ruiz L. et al. - Ocular tolerance to a topical formulation of hyaluronic acid and chitosan-based nanoparticles. - Cornea., 29 (5), 550-558, 2010.
171. Nagarwal R.C., Singh P.N., Kant S., Maiti P., Pandit J.K. - Chitosan nanoparticles of 5-fluorouracil for ophthalmic delivery: characterization, in vitro and in vivo study. - Chem. Pharm. Bull., 59 (2), 272-278, 2011.
172. Rabinovich-Guilatt L., Couvreur P., Lambert G., Dubernet C. - Cationic vectors in ocular drug delivery. - J. Drug Target., 12 (9-10), 623-633, 2004. (Pubitemid 40100710)
173. Steger L.D., Desnick R.J. - Enzyme therapy. VI: Comparative In vivo fates and effects on lysosomal integrity of enzyme entrapped in negatively and positively charged liposomes. -Biochim. Biophys. Acta, 464 (3), 530-546, 1977. (Pubitemid 8023742)
174. Yoshihara E.N.T. - Cytolytic activity of liposomes containing stearylamine. - Biochim. Biophys. Acta, 854 (1), 93-101, 1986. (Pubitemid 16165481)
175. Schaeffer H.E., Krohn D.L. - Liposomes in topical drug delivery. - Invest. Ophthalmol. Vis. Sci., 22 (2), 220-227, 1982.
176. Klang S.H., Hoffman A., Benita S. - Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle. - J. Pharm. Pharmacol., 46 (12), 986-993, 1994.
177. Abdelkader H., Ismail S., Hussein A., Wu Z., Al-Kassas R., Alany R.G. - Conjunctival and corneal tolerability assessment of ocular naltrexone niosomes and their ingredients on the hen's egg chorioallantoic membrane and excised bovine cornea models. - Int. J. Pharm., 432 (1-2), 1-10, 2012.
178. Malik N. et al. - Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125-labelled polyamidoamine dendrimers in vivo. - J. Control. Rel., 65 (1-2), 133-148, 2000. (Pubitemid 30122922)
179. Aillon K.L., Xie Y., El-Gendy N., Berkland C.J. Forrest M.L. -Effects of nanomaterial physicochemical properties on in vivo toxicity. - Adv. Drug. Deliv. Rev., 61 (6), 457-466, 2009.
180. Vandamme T.F., Brobeck L. - Poly(amidoamine) dendrimers as ophthalmic vehicles for ocular delivery of pilocarpine nitrate and tropicamide. - J. Control. Release., 102 (1), 23-38, 2005.
181. Lopez A.I., Reins R.Y., McDermott A.M., Trautner B.W., Cai C. - Antibacterial activity and cytotoxicity of PEGylated poly(amidoamine) dendrimers. - Mol. Biosyst., 5 (10), 1148-1156, 2009.
182. Giordano G.G., Chevez-Barrios P., Refojo M.F., Garcia C.A. -Biodegradation and tissue reaction to ¡ntravitreous biodegradable poly(D,L-lactic-co-glycolic)acid microspheres. - Curr. Eye Res., 14 (9), 761-768, 1995.
183. Moritera T., Ogura Y., Honda Y., Wada R., Hyon S.H., Ikada Y. - Microspheres of biodegradable polymers as a drug-delivery system in the vitreous. - Invest. Ophthalmol. Vis. Sci., 32 (6), 1785-1790, 1991.
184. Khoobehi B., Stradtmann M.O., Peyman G.A., Aly O.M. - Clearance of sodium fluorescein incorporated into microspheres from the vitreous after intravitreal injection. - Ophthalmic Surg., 22 (3), 175-180, 1991.
185. Veloso A.A., Zhu Q., Herrero-Vanrell R., Refojo M.F. - Ganciclovir-loaded polymer microspheres in rabbit eyes inoculated with human cytomegalovirus. - Invest. Ophthalmol. Vis. Sci., 38 (3), 665-675, 1997. (Pubitemid 27143138)
186. Visscher G.E., Robison R.L., Maulding H.V., Fong J.W., Pearson J.E., Argentieri G.J. - Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. - J. Biomed. Mater. Res., 19 (3), 349-365, 1985. (Pubitemid 15101377)
187. Gupta H., Aqil M., Khar R.K., All A., Bhatnagar A., Mittal G. -Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. - Nanomedicine, 6 (2), 324-333, 2010.
188. Zhang L., Li Y., Zhang C., Wang Y., Song C. - Pharmacokinetics and tolerance study of intravitreal injection of dexamethasone-loaded nanoparticles in rabbits. - Int. J. Nanomedicine, (4), 175-183, 2009.
189. Barbosa-Alfaro D., Fernandez-Bueno I., Kadam R.S., García- Gutierrez M.T., Molina-Martínez I.T., Kompella U.B., PastorJimeno J.C., Herrero-Vanrell R. - Dexamethasone loaded plga microspheres destined to periocular administration. In vitro and in vivo studies. - Submitted to Exp. Eye Res., 2012.
190. Saishin Y., Silva, RL., Callahan, K., Schoch, C., Ahlheim, M., Lai, H., Kane, F., Brazzell, RK., Bodmer, D., Campochiaro, PA. - Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. - Invest. Ophthalmol. Vis. Sci., 44 (11), 4989-4993, 2003. (Pubitemid 37315317)
191. Merodio M., Irache J.M., Valamanesh F., Mirshahi M. - Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. - Biomaterials, 23 (7), 1587-1594, 2002. (Pubitemid 34158581)
192. Silva-Cunha A., Pialho S.L., Naud M.C., Behar-Cohen F. - Polyepsilon-caprolactone ¡devices: an in vivo study. - Invest. Ophthalmol. Vis. Sci., 50 (5), 2312-2318, 2009.
193. Rincon A.C. et al. - Biocompatibility of elastin-like polymer poly(VPAVG) microparticles: in vitro and in vivo studies. - J. Biomed. Mater. Res A., 78 (2), 343-351, 2006. (Pubitemid 44061072)
194. Del Amo E.M. - Current and future ophthalmic drug delivery systems: a shift to the posterior segmen. - Drug Discov. Today, 13 (3-4), 135-143, 2008.
195. Mishra M.B., Baqui M., Tamboli V., Mitra A.K. - Recent applications of liposomes in ophthalmic drug delivery. - J. Drug Deliv., 863-734, 2011.
196. Merodio M., Irache J.M., Valamanesh F., Mirshahi M. - Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in rats. - Biomaterials, 23 (7), 1587-1594, 2002. (Pubitemid 34158581)
197. Tremblay C., Barza M., Szoka F., Lahav M., Baum J. - Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits. - Invest. Ophthalmol. Vis. Sci., 26 (5), 711-718, 1985. (Pubitemid 15067812)
198. Shakiba S.A.K., Listhaus A.D., Munguia D., Flores-Aguilar M, Vuong C, Wiley C.A., Tolman R.L., Karkas J.D., Bergeron-Lynn G., Freeman W.R. - Evaluation of retinal toxicity and liposome encapsulation of the anti-CMV drug 2′-nor-cyclic GMP. - Invest. Ophthalmol. Vis. Sci., 34 (10), 2903-2910, 1993. (Pubitemid 23269144)
199. Zimmer A. - Microspheres and nanoparticles used in ocular delivery systems. - Adv. Drug. Deliv. Rev., 16, 61-73, 1995.
200. Sensoy D., Cevher, E., Sarici, A., Yilmaz, M., Ozdamar, A., Bergisadi, N. - Bioadhesive sulfacetamide sodium microspheres: evaluation of their effectiveness in the treatment of bacterial keratitis caused by Staphylococcus aureus and Pseudomonas aeruginosa in a rabbit model. - Eur. J. Pharm. Biopharm., 72 (3), 487-495, 2009.
201. Addo R.T., Siddig, A., Siwale, R., Patel, N. J., Akande, J., Uddin, A. N., D'Souza, M. J. - Formulation, characterization and testing of tetracaine hydrochloride-loaded albumin-chitosan microparticles for ocular drug delivery. - J. Microencapsul., 27 (2), 95-104, 2010.
202. Choy Y.B. P.J.H., Prausnitz M.R. - Mucoadhesive microparticles engineered for ophthalmic drug delivery. - J. Phys. Chem. Solids., 69 (5-6), 1533-1536, 2008.
203. Choy Y.B., Park J.H., McCarey B.E., Edelhauser H.F., Prausnitz M.R. - Mucoadhesive microdiscs engineered for ophthalmic drug delivery: effect of particle geometry and formulation on preocular residence time. - Invest. Ophthalmol. Vis. Sci., 49 (11), 4808-4815, 2008.
204. Moritera T. et al. - Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. -Invest. Ophthalmol. Vis. Sci., 33 (11), 3125-3130, 1992.
205. Giordano G.G., Refojo M.F., Arroyo M.H. - Sustained delivery of retlnoic acid from microspheres of biodegradable polymer in PVR. - Invest. Ophthalmol. Vis. Sci., 34 (9), 2743-2751, 1993. (Pubitemid 23232484)
206. Conte U.G.P.I., Puglisi G. - Biodegradable microspheres for the intravitreal administration of acyclovir: in vitro/in vivo evaluation. - Eur. J. Pharm. Sci., 5, 287-293, 1997. (Pubitemid 27397783)
207. Duwuri S., Janorla K.G., Pal D., Mitra A.K. - Controlled delivery of ganciclovir to the retina with drug-loaded poly(d,L-lactide-co-glycolide) (PLGA) microspheres dispersed in PLGA-PEG-PLGA Gel: a novel intravitreal delivery system for the treatment of cytomegalovirus retinitis. - J. Ocul. Pharmacol. Ther., 23 (3), 264-274, 2007. (Pubitemid 46986607)
208. He Y. et al. - Cyclosporine-loaded microspheres for treatment of uveitis: in vitro characterization and in vivo pharmacokinetic study. - Invest. Ophthalmol. Vis. Sci., 47 (9), 3983-3988, 2006. (Pubitemid 46044315)
209. Barcia E., Herrero-Vanrell R., Diez A., Alvarez-Santiago C., Lopez L., Calonge M. - Downregulation of endotoxin-induced uveitis by intravitreal injection of polylactic-glycolic acid (PLGA) microspheres loaded with dexamethasone. - Exp. Eye Res., 89 (2), 238-245, 2009.
210. Jiang C., Moore M.J., Zhang X., Klassen H., Langer R., Young M. - Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. - Mol. Vis., 13, 1783-1792, 2007. (Pubitemid 47497006)
211. Ward M.S., Khoobehi A., Lavik E.B., Langer R., Young M.J. -Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres. - J. Pharm. Sci., 96 (3), 558-568, 2007. (Pubitemid 46466078)
212. Amrite A., Kompella U. - Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. - J. Pharm. Pharmacol., 57 (12), 1555-1563, 2005. (Pubitemid 41752269)
213. Kompella U., Bandi N., Ayalasomayajula S.P. - Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. - Invest. Ophthalmol. Vis. Sci., 44 (3), 1192-1201, 2003. (Pubitemid 36297840)
214. Ayalasomayajula S., Kompella UB. - Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress ¡n a rat model. - Eur. J. Pharmacol., 511 (2-3), 191-198, 2005. (Pubitemid 40417726)
215. Kimura H., Ogura, Y., Moritera, T., Honda, Y., Wada, R., Hyon, S. H., Ikada, Y. - Injectable microspheres with controlled drug release for glaucoma filtering surgery. - Invest. Ophthalmol. Vis. Sci., 33 (12), 3436-3441, 1992.
216. Gomes dos Santos A., Bochot, A., Doyle, A., Tsapis, N., Siepmann, J. Siepmann, F., Schmaler, J., Besnard, M., Behar-Cohen, F., Fattal, E. - Sustained release of nanosized complexes of polyethylenimine and anti-TGF-beta 2 oligonucleotide improves the outcome of glaucoma surgery. - J. Control. Release., 112 (3), 369-381, 2006. (Pubitemid 43737146)
217. Carrasquillo K.G., Ricker, J. A., Rigas, I. K., Miller, J. W., Gragoudas, E. S., Adamis, A. P. - Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres. - Invest. Ophthalmol. Vis. Sci., 44 (1), 290-299, 2003. (Pubitemid 36134287)
218. Vega E., Egea M.A., Valls O., Espina M., García M.L. - Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. - J. Pharm. Sci., 95 (11), 2393-2405, 2006. (Pubitemid 44726380)
219. Lallemand F., Pelt-Baeyens O., Besseghir K., Behar-Cohen F., Gumy R. - Cyclosporine A delivery to the eye: A pharmaceutical challenge. - Eur. J. Pharm. Biopharm., 56 (3), 307-318, 2003. (Pubitemid 37346503)
220. Singh K.H., Shinde U.A. - Chitosan nanoparticles for controlled delivery of brimonidine tartrate to the ocular membrane. -Pharmazie, 66 (8), 594-599, 2011.
221. Kao H.J., Lin H.R.,Lo Y.L., Yu S.P. - Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles. - J. Pharm. Pharmacol., 58 (2), 179-186, 2006.
222. Wadhwa S., Paliwal R., Paliwal S.R., Vyas S.P. - Hyaluronic acid modified chitosan nanoparticles for effective management of glaucoma: development, characterization, and evaluation. - J. Drug Target., 18 (4), 292-302, 2010.
223. Jwala J., Boddu S.H., Shah S., Sirimulla S., Pal D., Mitra A.K. - Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir. - J. Ocul. Pharmacol., Ther., 27 (2), 163-172, 2011.
224. Konat Zorzi G. et al. - Expression of MUC5AC in ocular surface epithelial cells using cationized gelatin nanoparticles. - Mol. Pharm., 8 (5), 1783-1788, 2011.
225. Liu Z. et al. - Preparation and evaluation of solid lipid nanoparticles of baicalin for ocular drug delivery system in vitro and in vivo. - Drug. Dev. Ind. Pharm., 37 (4), 475-481, 2011.
226. Cavalli R., Gaseo M.R., Chetoni P., Burgalassi S., Saettone M.F. - Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. - Int. J. Pharm., 238 (1-2), 241-245, 2002. (Pubitemid 34457892)
227. Seyfoddin A., Al-Kassas R. - Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. - Drug Dev. Ind. Pharm., 2012.
228. Li R. et al. - A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide. - J. Microencapsul., 28 (2), 134-141, 2011.
229. Attama A.A., Reichl S., Miiller-Goymann C.C. - Sustained release and permeation of timolol from surface-modified solid lipid nanoparticles through bioengineered human cornea. - Curr. Eye Res., 34 (8), 698-705, 2009.
230. Gõkçe E.H., Sandri G., Eǧrilmez S., Bonferoni M.C., Güneri T., Caramella C. - Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release In rabbit eyes. - Curr. Eye Res., 34 (11), 996-1003, 2009.
231. Delgado D. et al. - Dextran and protamine-based solid lipid nanoparticles as potential vectors for the treatment of X-linked juvenile retinoschisis. - Hum Gene Ther., 2012.
232. Robinson R. et al. - Nanospheres delivering the EGFR TKI AG1478 promote optic nerve regeneration: the role of size for intraocular drug delivery. - ACS Nano., 5 (6), 4392-4400, 2011.
233. Yoshida T., Gong J., Xu Z., Wei Y., Duh E.J. - Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac). - Exp. Eye Res., 94 (1), 41-48, 2012.
234. Park K. et al. - Nanoparticle-mediated expression of an angiogenic inhibitor ameliorates ischemia-induced retinal neovascularization and diabetes-induced retinal vascular leakage. - Diabetes., 58 (8), 1902-1913, 2009.
235. Farjo R., Skaggs J., Quiambao A.B., Cooper M.J., Naash M.I. - Efficient non-viral ocular gene transfer with compacted DNA nanoparticles. - PLoS One, 1(e)38, 2006.
236. Hayashi A., Naseri A., Pennesi M.E., de Juan E. - Subretinal delivery of immunoglobulin G with gold nanoparticles in the rabbit eye. - Jpn. J. Ophthalmol., 53 (3), 249-256, 2009.
237. Cai X., Conley S.M., Nash Z., Fliesler S.J., Cooper M.J., Naash M.I. - Gene delivery to mitotic and postmitotic photoreceptors via compacted DNA nanoparticles results in improved phenotype in a mouse model of retinitis pigmentosa. - Faseb J., 24 (4), 1178-1191, 2010.
238. Amrite A.C., Edelhauser H.F., Singh S.R., Kompella U.B. - Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration. - Mol. Vis., 14, 150-160, 2008. (Pubitemid 351194002)
239. Amrite A.C., Kompella U.B. - Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. - J. Pharm. Pharmacol., 57 (12), 1555-1563, 2005. (Pubitemid 41752269)
240. Kompella U.B., Bandi N., Ayalasomayajula S.P. - Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. - Invest. Ophthalmol. Vis. Sci., 44 (3), 1192-1201, 2003. (Pubitemid 36297840)
241. Zuidam N.J., Hirsch-Lerner D., Margulies S., Barenholz Y. -Lamellarity of cationic liposomes and mode of preparation of lipoplexes affect transfection efficiency. - Biochim. Biophys. Acta, 1419 (2), 207-220, 1999. (Pubitemid 29322711)
242. Gipson I.K. - Distribution of mucins at the ocular surface. - Exp. Eye Res., 78 (3), 379-388, 2004.
243. Law S.L. - Properties of acyclovir-containing liposomes for potential ocular delivery. - Int. J. of Pharm., 161 (2), 253-259, 1999. (Pubitemid 28095709)
244. Chetoni P., Burgalassi S., Monti D., Mariotti S., Saettone M.F. - Comparison of liposome-encapsulated acyclovir with acyclovir ointment: ocular pharmacokinetics in rabbits. - J. Ocul. Pharmacol. Ther., 20 (2), 169-177, 2004. (Pubitemid 38456590)
245. Shen Y., Tu J. - Preparation and ocular pharmacokinetics of ganciclovir liposomes. - AAPS J., 9 (3), E371-377, 2007. (Pubitemid 351801759)
246. Ding S. - Recent developments in ophthalmic drug delivery. -Pharmaceutical Science & Technology Today., 1 (8), 328-335, 1998. (Pubitemid 28526961)
247. Budai L. et al. - Gels and liposomes ¡n optimized ocular drug delivery: studies on ciprofloxacin formulations. - Int. J. Pharm., 343 (1-2), 34-40, 2007. (Pubitemid 47334864)
248. Greaves J.L., Wilson C.G. - Treatment of diseases of the eye with mucoadhesive delivery systems. - Adv. Drug Deliv. Rev., 11 (3), 349-383, 1993. (Pubitemid 23302852)
249. Wilson C.G., Zhu Y.P., Frier M., Rao L.S., Gilchrist P., Perkins A.C. - Ocular contact time of a carbomer gel (GelTears) in humans. - Br. J. Ophthalmol., 82 (10), 1131-1134, 1998. (Pubitemid 28474866)
250. Ludwig A. - The use of mucoadhesive polymers in ocular drug delivery. - Adv. Drug Deliv. Rev., 57 (11), 1595-1639, 2005. (Pubitemid 41443472)
251. Hosny K.M. - Ciprofloxacin as ocular liposomal hydrogel. - AAPS PharmSciTech., 11 (1), 241-246, 2010.
252. Hosny K.M. - Optimization of gatifloxacin liposomal hydrogel for enhanced transcorneal permeation. - J. Liposome Res., 20 (1), 31-37, 2010.
253. Hosny K. - Preparation and evaluation of thermosensitive liposomal hydrogel for enhanced transcorneal permeation of ofloxacin. - AAPS PharmSciTech., 10 (4), 1336-1342, 2009.
254. Milsmann M.H., Weder H.G. - The preparation of large single bilayer liposomes by a fast and controlled dialysis. - Biochim. Biophys. Acta, 512 (1), 147-155., 1978. (Pubitemid 9005594)
255. Milani J.K. et al.- Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. - Ophthalmology, 100 (6), 890-896, 1993. (Pubitemid 23163500)
256. Pleyer U.E.B., Rückert D., Lutz S., Grammer J., Chou J., Schmidt K.H., Mondino B.J. - Ocular absorption of cyclosporine A from liposomes incorporated into collagen shields. - Curr. Eye Res., 13 (3), 177-181, 1994. (Pubitemid 24088421)
257. Monem A.S., Ali P.M., Ismail M.W. - Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. - Int. J. Pharm., 198 (1), 29-38, 2000. (Pubitemid 30155547)
258. El-Gazayerly O.N., Hikal A.H. - Preparation and evaluation of acetazolamide liposomes as an ocular delivery system. - Int. J. Pharm. 158 (2), 121-127, 1997. (Pubitemid 28012898)
259. Bochot A., Fattal E. - Liposomes for intravitreal drug delivery: A state of the art. - J. Control. Rel., 161 (2), 628-634, 2012.
260. Cannon J.P. et al. - Comparative toxicity and concentrations of intravitreal amphotericin B formulations in a rabbit model. -Invest. Ophthalmol. Vis. Svi., 44 (5), 2112-2117, 2003. (Pubitemid 36520306)
261. Liu K.R., Peyman G.A., Khoobehi B. - Efficacy of liposome-bound amphotericin B for the treatment of experimental fungal endophthalmitis in rabbits. - Invest. Ophthalmol. Vis. Sci., 30 (7), 1527-1534, 1989. (Pubitemid 19185954)
262. Cheng L.H.K., Chaidhawangul S., Gardner M.F., Beadle J.R., Keefe K.S., Bergeron-Lynn G., Severson G.M, Soules K.A., Mueller A.J., Freeman W.R. - Intravitreal toxicology and duration of efficacy of a novel antiviral lipid prodrug of ganciclovir in liposome formulation. - Invest. Ophthalmol. Vis. Sci., 41 (6), 1523-1532, 2000. (Pubitemid 30261879)
263. Crooke S. - Vitravene, Another piece in the mosaic. - Antisense Nucleic Acid Drug Dev., 8 (4), 7-8, 1998.
264. Rayburn Z.R. - Antisense, RNAi, and gene silencing strategies for therapy: mission possible or Impossible? - Drug Discov. Today, 13 (11-12), 513-521, 2008.
265. Kawakami S. et al. - In vivo gene transfection via intravitreal injection of cationic liposome/plasmid DNA complexes in rabbits. - Int. J. Pharm., 278 (2), 255-262, 2004. (Pubitemid 38759498)
266. Peeters L.S.N., Braeckmans K., Boussery K., Van de Voorde J., De Smedt S.C., Demeester J. - Vitreous: a barrier to nonviral ocular gene therapy. - Invest. Ophthalmol. Vis. Sci., 46 (10), 3553-3561, 2005. (Pubitemid 44264656)
267. Bochot A. et al. - Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. - Invest. Ophthalmol. Vis. Sci., 43 (1), 253-259, 2002. (Pubitemid 34032467)
268. Lajavardi L. et al. - New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. - J. Control. Rel., 139 (1), 22-30, 2009.
269. Camelo S.L.L., Bochot A., Goldenberg B., Naud M.C., Pattal E., Behar-Cohen F., de Kozak Y. - Ocular and systemic biodistribution of rhodamine-conjugated liposomes loaded with VIP injected into the vitreous of Lewis rats. - Mol. Vis., 7 (13), 2263-2274, 2007. (Pubitemid 350268733)
270. Nesburn B.R., Ghiasi H., Slanina S., Bahri S., Wechsler S.L. - Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. - J. Viral., 68 (8), 5084-5092, 1994. (Pubitemid 24226576)
271. Nesburn S.S., Burke R.L., Ghiasi H., Bahri S., Wechsler S.L. - Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. - J. Virol., 72 (10), 7715-7721, 1998. (Pubitemid 28421761)
272. Caselll E B.P., Incorvaia C., Argnani R., Parmeggiani F., Cassai E., Manservigi R. - Local and systemic inoculation of DNA or protein gB1s-based vaccines induce a protective immunity against rabbit ocular HSV-1 infection. - Vaccine, 19 (9-10), 1225-1231, 2000. (Pubitemid 32008290)
273. Nesburn B.R., Ghiasi H., Slanina S.M., Wechsler S.L. - A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. - Invest. Ophthalmol. Vis. Sci., 39 (7), 1163-1170, 1998. (Pubitemid 28247350)
274. Barber L.D., Pflugfelder S.C., Tauber J., Poulks G.N. - Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. - Ophthalmology, 112 (10), 1790-1794, 2005. (Pubitemid 41400017)
275. Perry H.D., Doshi-Carnevale S., Donnenfeld E.D., Solomon R., Biser S.A., Bloom A.H. - Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. - Cornea, 25 (2), 171-175, 2006. (Pubitemid 43362715)
276. Fialho S. - New vehicle based on a microemulsion for topical ocular administration of dexamethasone. - Clin. Exp. Ophthalmol., 32 (6), 626-632, 2004. (Pubitemid 40081090)
277. Klang S., Abdulrazik M., Benita S. - Influence of emulsion droplet surface charge on indomethacin ocular tissue distribution. - Pharm. Dev. Technol., 5 (4), 521-532, 2000.
278. Chan J., El Maghraby, G., Craig, J.P., Alany, R.G. - Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. - Int. J. Pharm., 328, 65-71, 2007. (Pubitemid 44827562)
279. Li C.C., Abrahamson M., Kapoor Y., Chauhan A. - Timolol transport from microemulsions trapped in HEMA gels. - J. Colloid Interface Sci., 315 (1), 297-306, 2007. (Pubitemid 47410011)
280. Aggarwal D., Pal D., Mitra A.K., Kaur I.P. - Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. - Int. J. Pharm., 338 (1-2), 21-26, 2007. (Pubitemid 46777217)
281. Kaur I.P., Aggarwal D., Singh H., Kakkar S. - Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system. - Graefes Arch. Clin. Exp. Ophthalmol., 248 (10), 1467-1472, 2010.
282. Cheng Y., Xu Z. Ma M., Xu T. - Dendrimers as drug carriers: applications in different routes of drug administration. - J. Pharm. Sci., 97 (1), 123-143, 2008.
283. Andres-Guerrero V., Molina-Martinez I.T., Peral A., de las Heras B., Pintor J., Herrero-Vanrell R. - The use of mucoadhesive polymers to enhance the hypotensive effect of a melatonin analogue, 5-MCA-NAT, in rabbit eyes. - Invest. Ophthalmol. Vis. Sci., 52 (3), 1507-1515, 2011.
284. Sultana Y., Maurya D.P., Iqbal Z., Aqil M. - Nanotechnology in ocular delivery: current and future directions. - Drugs Today, 47 (6), 441-455, 2011.
285. Yao W. et al. - Preparation and characterization of puerarin-dendrimer complexes as an ocular drug delivery system. - Drug Dev. Ind. Pharm., 36 (9), 1027-1035, 2010.
286. Yao W.J. et al. - Effect of poly(amidoamine) dendrimers on corneal penetration of puerarin. - Biol. Pharm. Bull., 33 (8), 1371-1377, 2010.
287. Spataro G. et al. - Designing dendrimers for ocular drug delivery. - Eur. J. Med. Chem., 45 (1), 326-334, 2010.
288. Durairaj C., Kadam R.S., Chandler J.W., Hutcherson S.L., Kompella U.B. - Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin. - Invest. Ophthalmol. Vis. Sci., 51 (11), 5804-5816, 2010.
289. Durairaj C.K.U. - Dendritic polyguanidilyated translocators for ocular drug delivery. - Drug Deliv. Technol., 9, 36-43, 2009.
290. Chung H.H. et al. - Dendritic oligoguanidines as intracellular translocators. - Biopolymers, 76 (1), 83-96, 2004.
291. Wimmer N., Marano R.J., Kearns P.S., Rakoczy E.P., Toth I. - Syntheses of polycationic dendrimers on lipophilic peptide core for complexation and transport of oligonucleotides. - Bioorg Med. Chem. Lett., 12 (18), 2635-2637, 2002. (Pubitemid 35245297)
292. Marano R.J. et al. - Inhibition of in vitro VEGP expression and choroidal neovascularization by synthetic dendrimer peptide mediated delivery of a sense oligonucleotide. - Exp. Eye Res., 79 (4), 525-535, 2004. (Pubitemid 39223333)
293. Marano R.J., Toth L., Wimmer N., Brankov M., Rakoczy P.E. - Dendrimer delivery of an anti-VEGF oligonucleotide into the eye: a long-term study into inhibition of laser-induced CNV, distribution, uptake and toxicity. - Gene Ther., 12 (21), 1544-1550, 2005. (Pubitemid 41541772)
294. Parekh H.S., Marano R.J., Rakoczy E.P., Blanchfield J., Toth I. - Synthesis of a library of polycationic lipid core dendrimers and their evaluation ¡n the delivery of an oligonucleotide with hVEGP inhibition. - Bioorg Med Chem., 14 (14), 4775-4780, 2006. (Pubitemid 43767118)
295. Iezzi R., Guru B.R., Glybina I.V., Mishra M.K., Kennedy A., Kannan R.M. - Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. - Biomaterials, 33 (3), 979-988, 2012.
296. Shaunak S. et al. - Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. - Nat. Biotechnol., 22 (8), 977-984, 2004. (Pubitemid 39014474)
297. Kang S.J., Durairaj C., Kompella U.B., O'Brien J.M., Grossniklaus H.E. - Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. - Arch. Ophthalmol., 127 (8), 1043-1047, 2009.